Objective: Homeobox genes are transcriptional regulators that orchestrate embryonic development. The HOXA13 gene is responsible for the development of the vagina and regulates extracellular matrix constituents. We hypothesized that vaginal expression of HOXA13 may be decreased in women with pelvic organ prolapse (POP) and sought to determine if hypoestrogenism affects its expression.
P elvic organ prolapse (POP) is the result of weakened endopelvic fascia causing herniation of the uterus, bladder, bowel, and/or rectum into the vaginal canal. 1 POP has been shown to affect up to 30% of the female population. 2 It is also projected that over the next 30 years, the number of women seeking treatment for prolapse will double. 3 In addition to the rising numbers of women seeking treatment for POP, up to 30% of patients undergoing surgical repair develop recurrent POP, leading investigators to search for a better understanding of the underlying mechanisms of this disorder. 4 The pathophysiology of POP is thought to be multifactorial. Clinical risk factors for POP have been classically delineated as child birth, aging, menopause, and increasing body mass index (BMI). 1,5<7 More recent investigations have revealed that women with POP have decreased vaginal and uterosacral smooth muscle content and extracellular matrix (ECM) abnormalities, including changes in the dynamic balance in collagen content and expression of metalloproteinases in the vaginal ECM. 8<14 However, little is known regarding regulation of the ECM proteins and pathophysiological pathways associated with POP.
Estrogen has been shown to increase fibroblast proliferation, to positively affect collagen production, and to decrease expression of matrix metalloproteinases. 15<18 In postmenopausal women, collagen subtypes are altered in the endopelvic fascia, and hormones have been shown to restore the biomechanical properties of the vagina and supportive tissues after surgical menopause in young rats. 19, 20 Therefore, the influence of menopause on the ECM has been studied to determine pathways that estrogen may be involved in the development of POP.
Homeobox (HOX) genes are evolutionarily conserved genes encoding transcription factors that regulate mammalian embryonic growth and development of the urogenital tract. The HOXA cluster genes mediate segmental differentiation of the paramesonephric duct into morphologically distinct organs of the female reproductive tract. 21 These genes have been shown to persist in the adult reproductive tract and maintain plasticity of the genital tract during times of hormonal and structural changes that occur during the menstrual cycle and in pregnancy. 21<23 Previously, we have shown that HOXA11 is responsible for the development of the uterosacral ligament and is decreased in women with POP. 14 We have also shown that HOXA11 regulates collagen type III and matrix metalloproteinase expression in vitro. 14 HOXA13 is responsible for the development of the upper vagina. 21 Mutations in this gene cause the hand-foot-genital syndrome, which includes an array of vaginal structural abnormalities. 24<27 Microarray studies have shown that HOX genes regulate several ECM components. 28, 29 Because HOXA13 is a regulatory gene of the vagina, we hypothesized that alterations of expression of this gene may be involved in the development of POP. In this study, we determined that vaginal HOXA13 expression is decreased in women with POP. We also showed that in women with POP, the expression of HOXA13 is not affected by menopause. We have also shown that expression of HOXA13 is not altered in hypoestrogenic women receiving leuprolide acetate. These findings suggest that estrogen and HOXA13 work in separate pathways in ECM metabolism of the vagina.
METHODS

Acquisition of human tissue
All experiments were performed with approval of the Yale Human Investigation Committee. Vaginal specimens were collected between September 2005 and July 2007 from women undergoing hysterectomy or anterior vaginal repair at our institution. Before their surgery, a pelvic examination was performed to evaluate for the presence of POP. Vaginal prolapse was graded according to the POP quantification system advocated by the International Continence Society. 30 Women with stage II anterior wall prolapse or greater were assigned to the POP group. Data regarding age, menopause status, hormone use, and parity were recorded. Women with previous pelvic surgery, hormone use, and pessary use before surgery were excluded from the study.
At the time of surgery, 3-to 5-mm biopsies were taken from the midline anterior vaginal cuff for consistency. Specimens were divided in half. One section was promptly placed in RNAlater (Ambion, Inc) and stored at j80-C until extraction of RNA was performed. The other half was placed in 10% formalin for analysis using immunohistochemistry. Six specimens of the premenopausal POP group and three specimens from the postmenopausal POP group were very small, and in these cases, the tissue was processed for RNA extraction only.
Immunohistochemistry
Slides were prepared from 14 vaginal specimens obtained from premenopausal patients with POP, 22 from postmenopausal women with POP, 6 from premenopausal control women, and 5 from women with normal pelvic support who received leuprolide acetate. Formalin-fixed specimens were embedded in paraffin, sectioned (5 Km thickness), and fixed to glass slides. Immunohistochemistry was performed using a protocol that has been described previously. 14 HOXA13 antibody (made in rabbit, ab26084, Abcam, Inc, Cambridge, MA) in a 1:500 concentration was the primary antibody. Rabbit IgG as the primary antibody was used as a negative control. Duplicate slides of the primary antibody in addition to the negative controls were prepared for each specimen. Photographs of the slides were taken at a magnification of 600Â under the same lighting conditions using a Kodak DC290 Zoom digital camera (Eastman Kodak Company, Rochester, NY). Two observers evaluated the slides for intensity of staining.
RNA extraction
A total of 56 vaginal specimens were evaluated by real-time polymerase chain reaction (PCR) in this study; 20 vaginal specimens obtained from premenopausal women with POP, 25 from postmenopausal women with POP, 6 from premenopausal control women, and 5 from women with normal pelvic support who received leuprolide acetate. Specimens in RNAlater for RNA extraction were thawed on ice and placed in 1 mL of TRIzol per 100 mg tissue (Invitrogen Corporation). Tissue was homogenized on ice and total RNA was isolated using methodology described by the manufacturer. The optical density of the RNA was measured using SmartSpex 300 (Bio-Rad Laboratories, Inc) at 260 nm to determine the concentration. One microgram of high-purity RNA (optical density 260/280, ratios 1.8-2.0) was reversetranscribed using the Eppendorf Mastercycler (Eppendorf of North America) and the Bio-Rad iScript cDNA synthesis kit using conditions previously described. 14 The mRNA expression of vaginal HOXA13 was determined using real-time reverse transcriptase-PCR. The PCR primers used for amplification were 5 ¶-ATGCCTGGCTACCTG GATATGC-3 ¶ for the HOXA13 sense, 5 ¶-GGGCAGAGTG GACTTCCAGAGGT-3 ¶ for the HOXA13 antisense, 5 ¶-AGA GGAAATCGTGCGTGAC-3 ¶ for the A-actin sense, and 5 ¶-CAATAGTGACCTGGCCGT-3 ¶ for the A-actin antisense. The PCR reaction was carried out in a MyiQ real-time PCR detection system (Bio-Rad Laboratories, Inc). The melting peak of each sample was routinely determined by melting curve analysis to ascertain that only the expected products had been generated. Negative controls were run in the absence of reverse transcription. All specimens were run in duplicate and the experiments were repeated twice.
Gene expression levels of HOXA13 were standardized by calculating mRNA ratios relative to the housekeeping gene, A-actin. The formula 1/2 $Ct was used to compare relative values of RNA between groups. Fold changes were calculated using the formula 2 $$Ct .
Statistics
Descriptive data are expressed as mean T SEM and percentages. Parametric demographic data of the participants were compared between groups using the unpaired Student's t test. The results of relative mRNA expression between the groups were compared using a one-way analysis of variance with the Bonferroni correction. Statistical analysis was performed with Excel software (Microsoft Office 2003) and Sigma Stat. A P value less than 0.05 was considered statistically significant.
RESULTS
Demographic background of participants
The cohort in this study population was predominantly white (91.3%). The remainder of the participants consisted of women of African American (6.6%) and Hispanic (2.1%) ancestry. To evaluate the influence of estrogen status on HOXA13 expression, premenopausal controls were compared with premenopausal women receiving leuprolide acetate (a GnRH agonist) and premenopausal women with POP were compared with postmenopausal women with POP.
None of the postmenopausal women with POP were taking hormone therapy (HT). In the premenopausal POP group, nine women had stage II anterior vaginal wall prolapse and five women had stage III prolapse. In the postmenopausal POP group, 12 women had stage II anterior vaginal wall prolapse and 10 had stage III prolapse. No one in the study had stage IV disease. All women in the POP group underwent surgery for symptomatic prolapse. All of the women with POP had urinary incontinence and none of the controls had this condition.
For those women who received leuprolide acetate, one woman received one dose, two women received two doses, and two women received three doses before their surgery. All women received the last dose 3 to 4 weeks before their hysterectomy.
There were no differences in age, parity, or BMI between the premenopausal controls and the premenopausal POP group (Table 1) and between the premenopausal controls and the women receiving leuprolide acetate (data not shown). The postmenopausal POP group was significantly older than the premenopausal POP group but did not differ with regard to parity or BMI (data not shown).
Vaginal HOXA13 expression is lower in women with POP and not affected by menopause or exposure to leuprolide acetate
Immunohistochemistry demonstrated expression of HOXA13 in the vagina in women with and without prolapse; however, the positive immunoreactivity of intranuclear staining was consistently less pronounced in the prolapse group compared with control group (Fig. 1) . The immunoreactivity of the premenopausal and postmenopausal POP specimens was similar to each other, as was the immunoreactivity of the premenopausal control and the leuprolide specimens ( Fig. 1A-D) .
To quantitatively evaluate the vaginal expression of HOXA13 in each group of women, we used real-time reverse transcription-PCR. We found that the relative mRNA expression of HOXA13 of premenopausal women with POP was 14-fold lower compared with that of premenopausal controls (P G 0.001), despite similarities in age, parity, and BMI between the groups. The vaginal expression of HOXA13 was also significantly lower in postmenopausal POP specimens compared with controls (P G 0.001). In addition, the specimens of both the premenopausal and the postmenopausal women with POP had lower expression of HOXA13 compared with the specimens obtained from women receiving leuprolide acetate (P G 0.001 for both groups). There were no differences in vaginal expression of HOXA13 between premenopausal control specimens and specimens obtained from women exposed to leuprolide acetate (P = 1.0) or between specimens obtained from premenopausal women with POP and postmenopausal women with POP (P = 1.0) (Fig. 2) .
DISCUSSION
The present study demonstrates that HOXA13 expression is decreased in the vaginal tissues of women with POP and that expression of this gene is not affected by menopause or treatment with leuprolide acetate. Interestingly, the expression of HOXA13 was lower in the premenopausal women with POP compared with postmenopausal women with POP, although this was not statistically significant. In premenopausal women, inducing a hypoestrogenic state with a gonadotropin hormoneYreleasing hormone agonist did not affect HOXA13 expression.
Williams et al 29 demonstrated that HOXA13 regulates many genes involved in the ECM, including some that have been shown to be altered in women with POP. Their data revealed that expression of HOXA13 led to the up-regulation of several collagen types, which confer both the tensile strength of the vagina and basement membrane constituents. In addition, genes in the glycoprotein family were also upregulated by HOXA13 expression, including, fibulin, fibrillin 1, laminins 2 and 3, and osteonectin. 29 These genes are involved in the intricate networking of elastic fibers, basement membrane, microfibrils, and proteoglycan aggregates. 31<36 Mutations in this family of genes (filbrillin, fibulin, and osteonectin) are associated with POP in women and compromised ECM in mice. 31<33,36 Our findings of decreased HOXA13 expression in the vagina in women with POP and the data demonstrating that HOXA13 regulates many different structural components of the ECM strongly suggest that HOXA13 is a candidate gene for further investigation in determining the molecular mechanisms involved in the development of POP. These data are also consistent with our previous findings that HOXA11, another HOXA gene involved in the development of the uterus and uterosacral ligaments, is dramatically decreased in women with POP. Like HOXA13, changes in expression of HOXA11 was also independent of estrogen, age, parity, and BMI. 14 These findings combined suggest that HOX genes may be key regulators in the maintenance of the ECM of the uterine support structures and vagina.
A possible explanation for variable clinical presentation of POP is the existence of several pathways regulating the uro-genital ECM. We have demonstrated that there is a genetic predisposition for developing POP independent of menopause and leuprolide administration, which are associated with hypoestrogenism. Current in vitro and animal studies have shown that estrogen has positive effects on the ECM 15<17, 20 and others have shown that hypoestrogenism is associated with deterioration of the ECM and development of POP. 5<7, 19 The Women's Health Initiative demonstrated that conjugated equine estrogens alone and conjugated equine estrogens with medroxyprogestesrone increased the risk of urinary incontinence among continent women and worsened the characteristics of urinary incontinence in symptomatic women after 1 year of treatment. 37 Currently, there are no longitudinal studies evaluating the effect of HT on the quality of the ECM and its relationship with incontinence. It is possible that HT may benefit hypoestrogenic women with atrophic symptoms. However, HT may not prevent the development of POP in women who are genetically predisposed to this condition. The existence of two distinct pathways regulating the ECM in the vagina may explain the discrepant data on the effect of HT on urogenital symptoms.
CONCLUSIONS
Vaginal HOXA13 expression is diminished in women with POP compared with women with normal support. Expression of HOXA13 is not affected by menopause or exposure to leuprolide acetate, suggesting that estrogen and HOXA13 work through separate pathways in ECM metabolism of the vagina. Understanding genetic predispositions to developing POP may aid in identifying younger women at risk for this disease who would benefit from preventive strategies and not from estrogen therapy.
